Quantification of Myocardial Fibrosis in Aortis Stenosis

Enrolling by invitationOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

April 15, 2026

Conditions
Aortic Valve StenosisMyocardial Fibrosis
Interventions
DIAGNOSTIC_TEST

High frame rate echocardiography

Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.

DIAGNOSTIC_TEST

MRI

Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.

DIAGNOSTIC_TEST

Blood test

Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)

DIAGNOSTIC_TEST

ECG and Holter-ECG

ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.

DIAGNOSTIC_TEST

6 min walking test

6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.

Trial Locations (1)

7030

St. Olavs Hosptial, Trondheim

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

Oslo University Hospital

OTHER

lead

Norwegian University of Science and Technology

OTHER